USA flag logo/image

An Official Website of the United States Government

Artificial Lung Based on a Novel Microfluidic Technology

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
Program Year/Program:
2011 / SBIR
Agency Tracking Number:
R44HL091593
Solicitation Year:
2011
Solicitation Topic Code:
NHLBI
Solicitation Number:
PA10-050
Small Business Information
Infoscitex Corporation
303 Bear Hill Road Waltham, MA -
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 2
Fiscal Year: 2011
Title: Artificial Lung Based on a Novel Microfluidic Technology
Agency: HHS
Contract: 2R44HL091593-02A1
Award Amount: $1,519,727.00
 

Abstract:

DESCRIPTION (provided by applicant): Lung transplants remain the final treatment for many conditions. However, appropriate and available lungs are far fewer than the number of people who need them, leaving many patients to further deterioriate or die while waiting for a transplant. Moreover, there are many patients with insufficient lung function, including those suffering from lung cancer, who are not eligible for a lung transplant. Direct gas exchange between air and blood would provide respiratory support independent of injured lungs and allow the lungs to heal and recover. A device that can oxygenate using room air, rather than compressed air, and has a sufficiently small blood side pressure drop would greatly simplify and improve extracorporeal oxygenation. With the added requirements of long-term safety and efficacy, such a device would realize the final goal of a fully implantable artificial lung. Infoscitex has assembled a team of experts to further develop the technology for a family of vascular gasexchange devices. These devices use available room air and will likely reduce the need for anticoagulation methods compared to other devices currently available or in development. The research program detailed in this proposal will provide the necessary foundation to complete development of the technology for the implantable artificial lung, including initial animal trials. The proposed effort will result in the data necessary to secure the funding and approval for the next stage of device development andeventual market introduction. PUBLIC HEALTH RELEVANCE: The development of an implantable artificial lung based on direct vascular gas exchange performed directly from room air and requiring low levels of anticoagulation is proposed. Our device utilizes a novel two-stage gas exchange system that oxygenates blood via a liquid-liquid interface. This interface, by eliminating the contact of blood to a membrane, reduces fouling of the gas exchange surface which is the limiting factor in other devices under development.

Principal Investigator:

Anna M. Galea
781-890-1338
agalea@infoscitex.com

Business Contact:

Andrea L. Hicks
937-429-9008
ahicks@infoscitex.com
Small Business Information at Submission:

INFOSCITEX CORPORATION
303 BEAR HILL RD WALTHAM, MA -

EIN/Tax ID: 104353712
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No